Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders

Dong Chen, Mark E. Law, Jason D. Theis, Jeffrey D. Gamez, Lynn B. Caron, Julie A. Vrana, Ahmet Dogan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cyclin-dependent protein kinase 6 (CDK6), in cooperation with cyclin Ds, drives cell cycle progression from G1 to S phase through phosphorylation and subsequent inactivation of retinoblastoma 1 protein. Alteration of this pathway results in both nonhematologic and hematologic malignancies, which include a small subset of B-cell lymphoproliferative disorders (BLPDs). We identified 5 cases of BLPD that carried CDK6 chromosomal translocations and characterized their clinical, pathologic, immunophenotypic, and genetic features. Common clinical characteristics included marked neoplastic lymphocytosis, systemic lymphadenopathy, splenomegaly, and bone marrow involvement. Three patients were diagnosed with low-grade B-cell lymphoma and had an indolent clinical course, and 2 patients (one who transformed to large B-cell lymphoma, and the other who was initially diagnosed with a high-grade B-cell lymphoma) had an aggressive clinical course. Immunophenotypically, the neoplastic B cells expressed CD5, CDK6, and cytoplasmic retinoblastoma 1 protein in all cases, expressed phospho-RB, p27kip1, and cyclin D2 in most cases, and uniformly lacked expression of all other cyclins. In 4 cases, the CDK6 translocation partner was kappa immunoglobulin light-chain gene; and in the fifth case, the CDK6 translocation partner was unknown. These distinct clinicopathologic and cytogenetic features distinguish the CDK6 translocation-associated BLPDs (CDK6-BLPDs) from other mature B-cell lymphomas.

Original languageEnglish (US)
Pages (from-to)720-729
Number of pages10
JournalAmerican Journal of Surgical Pathology
Volume33
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Cyclin-Dependent Kinase 6
Lymphoproliferative Disorders
Cyclin-Dependent Kinases
B-Lymphocytes
B-Cell Lymphoma
Retinoblastoma Protein
Cyclins
Non-Hodgkin's Lymphoma
Immunoglobulin Light Chain Genes
Immunoglobulin kappa-Chains
Cyclin D2
B-Lymphocyte Subsets
Lymphocytosis
Genetic Translocation
Splenomegaly
Hematologic Neoplasms
S Phase
Cytogenetics
Cell Cycle
Bone Marrow

Keywords

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • Cyclin D
  • Cyclin-dependent protein kinase (CDK)
  • Mantle cell lymphoma (MCL)
  • Retinoblastoma protein (Rb)
  • Splenic marginal zone lymphoma (SMZL)

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery
  • Medicine(all)

Cite this

Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. / Chen, Dong; Law, Mark E.; Theis, Jason D.; Gamez, Jeffrey D.; Caron, Lynn B.; Vrana, Julie A.; Dogan, Ahmet.

In: American Journal of Surgical Pathology, Vol. 33, No. 5, 05.2009, p. 720-729.

Research output: Contribution to journalArticle

Chen, Dong ; Law, Mark E. ; Theis, Jason D. ; Gamez, Jeffrey D. ; Caron, Lynn B. ; Vrana, Julie A. ; Dogan, Ahmet. / Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. In: American Journal of Surgical Pathology. 2009 ; Vol. 33, No. 5. pp. 720-729.
@article{7e4b4def93e84d58ba9a60c0477ddac4,
title = "Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders",
abstract = "Cyclin-dependent protein kinase 6 (CDK6), in cooperation with cyclin Ds, drives cell cycle progression from G1 to S phase through phosphorylation and subsequent inactivation of retinoblastoma 1 protein. Alteration of this pathway results in both nonhematologic and hematologic malignancies, which include a small subset of B-cell lymphoproliferative disorders (BLPDs). We identified 5 cases of BLPD that carried CDK6 chromosomal translocations and characterized their clinical, pathologic, immunophenotypic, and genetic features. Common clinical characteristics included marked neoplastic lymphocytosis, systemic lymphadenopathy, splenomegaly, and bone marrow involvement. Three patients were diagnosed with low-grade B-cell lymphoma and had an indolent clinical course, and 2 patients (one who transformed to large B-cell lymphoma, and the other who was initially diagnosed with a high-grade B-cell lymphoma) had an aggressive clinical course. Immunophenotypically, the neoplastic B cells expressed CD5, CDK6, and cytoplasmic retinoblastoma 1 protein in all cases, expressed phospho-RB, p27kip1, and cyclin D2 in most cases, and uniformly lacked expression of all other cyclins. In 4 cases, the CDK6 translocation partner was kappa immunoglobulin light-chain gene; and in the fifth case, the CDK6 translocation partner was unknown. These distinct clinicopathologic and cytogenetic features distinguish the CDK6 translocation-associated BLPDs (CDK6-BLPDs) from other mature B-cell lymphomas.",
keywords = "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Cyclin D, Cyclin-dependent protein kinase (CDK), Mantle cell lymphoma (MCL), Retinoblastoma protein (Rb), Splenic marginal zone lymphoma (SMZL)",
author = "Dong Chen and Law, {Mark E.} and Theis, {Jason D.} and Gamez, {Jeffrey D.} and Caron, {Lynn B.} and Vrana, {Julie A.} and Ahmet Dogan",
year = "2009",
month = "5",
doi = "10.1097/PAS.0b013e3181934244",
language = "English (US)",
volume = "33",
pages = "720--729",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders

AU - Chen, Dong

AU - Law, Mark E.

AU - Theis, Jason D.

AU - Gamez, Jeffrey D.

AU - Caron, Lynn B.

AU - Vrana, Julie A.

AU - Dogan, Ahmet

PY - 2009/5

Y1 - 2009/5

N2 - Cyclin-dependent protein kinase 6 (CDK6), in cooperation with cyclin Ds, drives cell cycle progression from G1 to S phase through phosphorylation and subsequent inactivation of retinoblastoma 1 protein. Alteration of this pathway results in both nonhematologic and hematologic malignancies, which include a small subset of B-cell lymphoproliferative disorders (BLPDs). We identified 5 cases of BLPD that carried CDK6 chromosomal translocations and characterized their clinical, pathologic, immunophenotypic, and genetic features. Common clinical characteristics included marked neoplastic lymphocytosis, systemic lymphadenopathy, splenomegaly, and bone marrow involvement. Three patients were diagnosed with low-grade B-cell lymphoma and had an indolent clinical course, and 2 patients (one who transformed to large B-cell lymphoma, and the other who was initially diagnosed with a high-grade B-cell lymphoma) had an aggressive clinical course. Immunophenotypically, the neoplastic B cells expressed CD5, CDK6, and cytoplasmic retinoblastoma 1 protein in all cases, expressed phospho-RB, p27kip1, and cyclin D2 in most cases, and uniformly lacked expression of all other cyclins. In 4 cases, the CDK6 translocation partner was kappa immunoglobulin light-chain gene; and in the fifth case, the CDK6 translocation partner was unknown. These distinct clinicopathologic and cytogenetic features distinguish the CDK6 translocation-associated BLPDs (CDK6-BLPDs) from other mature B-cell lymphomas.

AB - Cyclin-dependent protein kinase 6 (CDK6), in cooperation with cyclin Ds, drives cell cycle progression from G1 to S phase through phosphorylation and subsequent inactivation of retinoblastoma 1 protein. Alteration of this pathway results in both nonhematologic and hematologic malignancies, which include a small subset of B-cell lymphoproliferative disorders (BLPDs). We identified 5 cases of BLPD that carried CDK6 chromosomal translocations and characterized their clinical, pathologic, immunophenotypic, and genetic features. Common clinical characteristics included marked neoplastic lymphocytosis, systemic lymphadenopathy, splenomegaly, and bone marrow involvement. Three patients were diagnosed with low-grade B-cell lymphoma and had an indolent clinical course, and 2 patients (one who transformed to large B-cell lymphoma, and the other who was initially diagnosed with a high-grade B-cell lymphoma) had an aggressive clinical course. Immunophenotypically, the neoplastic B cells expressed CD5, CDK6, and cytoplasmic retinoblastoma 1 protein in all cases, expressed phospho-RB, p27kip1, and cyclin D2 in most cases, and uniformly lacked expression of all other cyclins. In 4 cases, the CDK6 translocation partner was kappa immunoglobulin light-chain gene; and in the fifth case, the CDK6 translocation partner was unknown. These distinct clinicopathologic and cytogenetic features distinguish the CDK6 translocation-associated BLPDs (CDK6-BLPDs) from other mature B-cell lymphomas.

KW - Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

KW - Cyclin D

KW - Cyclin-dependent protein kinase (CDK)

KW - Mantle cell lymphoma (MCL)

KW - Retinoblastoma protein (Rb)

KW - Splenic marginal zone lymphoma (SMZL)

UR - http://www.scopus.com/inward/record.url?scp=65449165606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449165606&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3181934244

DO - 10.1097/PAS.0b013e3181934244

M3 - Article

VL - 33

SP - 720

EP - 729

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -